Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally administered, direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* Inhibition of thrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Adult Dosing
* **ACS:** Loading dose: 180 mg orally once. Maintenance dose: 90 mg orally twice daily.
* **History of MI (at least 1 year post-ACS/MI):** 60 mg orally twice daily.
* Duration of therapy: Typically 12 months, but may be extended in select patients based on risk assessment.
## Pediatric Dosing
* There is no established pediatric dosing for ticagrelor. Its use in pediatric patients is not recommended.
## Dose Adjustments
* **Hepatic Impairment:**
* **Mild to moderate:** No dose adjustment required.
* **Severe:** Use with caution; data is limited.
* **Renal Impairment:** No dose adjustment required.
## Contraindications
* Hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding.
* History of intracranial hemorrhage.
## Adverse Effects
* **Most Common:** Bleeding (major and minor), dyspnea, bradycardia, ventricular pauses, hyperuricemia, creatinine elevation.
* **Serious:** Significant bleeding, life-threatening bleeding.
## Key Drug Interactions
* **CYP3A4 Substrates/Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure.
* **CYP3A4 Substrates (e.g., simvastatin, atorvastatin):** Ticagrelor can increase plasma concentrations of CYP3A4 substrates.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use caution and consider risks/benefits.
* **Aspirin:** Generally co-administered for ACS, but prolonged use beyond 12 months with low-dose aspirin in patients with a history of MI (at least 1 year post-ACS/MI) has shown increased bleeding without a significant reduction in ischemic events.
* **NSAIDS:** Increased risk of bleeding.
* **Morphine and Opioids:** May delay absorption of ticagrelor and reduce plasma concentrations. Consider timing of administration.
## Monitoring
* **Bleeding:** Monitor closely for signs and symptoms of bleeding, especially in patients with increased bleeding risk factors.
* **Renal function:** Monitor creatinine, particularly in patients with pre-existing renal impairment.
* **Uric acid:** Monitor if hyperuricemia develops or worsens.
* **ECG:** Monitor for bradycardia if clinically indicated.
## Clinical Pearls
* Ticagrelor's onset of action is rapid.
* It is a reversible inhibitor, which may be advantageous in patients requiring urgent surgery.
* Dyspnea is a common side effect and is usually not clinically significant, but it warrants evaluation to rule out other causes.
* Avoid concurrent use with strong CYP3A4 inhibitors or inducers unless absolutely necessary and with careful monitoring.
* The 60 mg twice daily dose is indicated for long-term maintenance in patients who are at least 1 year out from ACS/MI and are not currently experiencing an active ACS.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.*
